How many institutions held NVCT - Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share in Q1 2026?

62 institutional investors reported NVCT - Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share for Q1 2026. Use the holders table for investor-level position and value details.

Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share (NVCT)

Q: What does CUSIP 67080T108 represent in this 13F holders report?

CUSIP 67080T108 is the security identifier for NVCT - Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share used to aggregate holder disclosures.

CUSIP: 67080T108

Q1 2026 13F Holders as of 31 Mar 2026

Security type / class: Equity / Common Stock, par value $0.00001 per share
Total 13F shares: 4,519,840
Total 13F value: $34,936,893
Share change: +268,584
Put/Call ratio: 0%
SEC-reported price per share: $7.73
Number of holders: 62
Value change: +$2,076,848
Number of buys: 33
Number of sells: 10
Shares outstanding: 32,314,196

Security key

67080T108

Report period

Q1 2026

Institutions

Top holders

NVCT full security history Ownership snapshot Full 13F holder table Nuvectis Pharma, Inc. SEC filings Nuvectis Pharma, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of NVCT - Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Enrique Poradosu

Disclosed value leader

Enrique Poradosu

Comparable rows

15/15

Latest evidence

06 Jan 2026

3/4/5 13F Lead comparable stake: 5.6% Showing 1-6 of 15 holder rows.

Quick read

Enrique Poradosu leads the comparable SEC ownership view at 5.6%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Enrique Poradosu's linked filing trail.

Comparable ownership Top 5

Enrique Poradosu 5.6%

Shay Shemesh 5.5%

VANGUARD GROUP INC 2.6%

BlackRock, Inc. 2.4%

IRIDIAN ASSET MANAGEMENT LLC/CT 1.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Enrique Poradosu	3/4/5 Chief Science & Business Off 3/4/5	5.6%	$13,637,527 1,806,319 shares	—	06 Jan 2026
Shay Shemesh	3/4/5 Chief Dev. & Ops. Officer 3/4/5	5.5%	$13,537,484 1,793,068 shares	—	06 Jan 2026
VANGUARD GROUP INC	13F Company 13F	2.6%	$6,383,541 845,502 shares	—	31 Dec 2025
BlackRock, Inc.	13F Company 13F	2.4%	$5,910,179 782,805 shares	—	31 Dec 2025
IRIDIAN ASSET MANAGEMENT LLC/CT	13F Company 13F	1.8%	$4,426,716 586,320 shares	—	31 Dec 2025
BALDWIN WEALTH PARTNERS LLC/MA	13F Company 13F	1.2%	$2,941,669 389,625 shares	—	31 Dec 2025

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

4,519,840

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q1 2026 Across Filers

Q1 2026 holders

Holder diff

Investor	Q1 2026 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q1 2026 value	Q1 2026 value	Value change	Value Chg %